The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia
Open accessAbstract
Sum m a r yHypoxia-inducible factors are transcription factors controlling energy, iron metabolism, erythropoiesis, and development.When these proteins are dysregulated, they contribute to tumorigenesis and cancer progression.However, mutations in genes encoding α subunits of hypoxia-inducible factors (HIF-α) have not previously been identified in any cancer.Here we report two novel somatic gain-of-function mutations in the gene encoding hypoxia-inducible factor 2α (HIF2A) in two patients, one presenting with paraganglioma and the other with paraganglioma and somatostatinoma, both of whom had polycythemia.The two mutations were associated with increased HIF-2α activity and increased protein half-life.H ypoxia-inducible factors, originally described by Wang et al., 1 are transcription factors that respond to changes in tissue oxygen concentration.These highly conserved proteins are composed of α and β subunits.The HIF-β subunit is constitutively expressed, whereas the α subunits are inducible by hypoxia and are associated with aggressive, treatment-refractory tumors.2,3 Under normoxic conditions, HIF-1α, HIF-2α, and HIF-3α are hydroxylated on specific prolyl residues, allowing for recognition by the von Hippel-Lindau (VHL) tumorsuppressor protein, ubiquitination, and rapid degradation through the proteasome.4 Under hypoxic conditions, prolyl hydroxylation of HIF-α proteins is reduced, resulting in their stabilization and, in turn, transcription of genes involved in the hypoxia response, including angiogenesis, glycolysis, apoptosis, proliferation, and growth.5,6 Paragangliomas and pheochromocytomas are catecholamine-producing tumors derived from the chromaffin cells of extraadrenal paraganglia and the adrenal medulla.7 The pioneering work of Neumann et al. 8 showed that about one fourth of these tumors were hereditary, a fraction that was subsequently estimated to be closer to one third, on the basis of the identification of mutations in several additional genes, including SDHA, SDHAF2, TMEM127, and MAX. 9 The identification of these genetic drivers led to the demonstration of HIF-α stabilization and dysregulation in paragangliomas and pheochromocytomas harboring mutations in VHL and succinate dehydrogenase (SDH).10,11 Somatostatinomas are somatostatin-producing neuroendocrine tumors believed to originate from neural-crest cells.They are occasionally diagnosed in patients with the VHL syndrome, multiple endocrine neoplasia type 1 or 2, or neurofibromatosis type 1. 12
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Somatic gain-of-function mutations in HIF2A have been discovered in pheochromocytomas and paragangliomas (Zhuang et al., 2012;Comino-Mendez et al., 2013;Lorenzo et al., 2013;Taieb et al., 2013;Toledo et al., 2013;Yang et al., 2013), while high HIF-2α expression is associated with poor survival in patients with neuroblastoma (Holmquist-Mengelbier et al., 2006).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Zhuang et al., 2012
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Lenders, J. W. M., Eisenhofer, G., Mannelli, M., & Pacák, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,541
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,350
Flagged first, then by citations
Research works printed but not linked: 3
- Vinik AI, 1987, Semin Oncol, 14, 263
- Morris MR, 2009, Anticancer Res, 29, 4337
- Prchal JT, 2008, N Engl J Med, 358, 1966
Cited by
Sorted by citations
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
Fishbein, L. M., Leshchiner, I., Walter, V., Danilova, L., Robertson, A. G., Johnson, A. R., Lichtenberg, T. M., Murray, B. A., Ghayee, H. K., Else, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.001 · Cited by 810
Regulation of erythropoiesis by hypoxia-inducible factors
Haase, V. H. (2013) · Blood Reviews · doi:10.1016/j.blre.2012.12.003 · Cited by 787
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“Somatic gain-of-function mutations in HIF2A have been discovered in pheochromocytomas and paragangliomas (Zhuang et al., 2012; Comino-Mendez et al., 2013; Lorenzo et al., 2013; Taieb et al., 2013; Toledo et al., 2013; Yang et al., 2013), while high HIF-2α expression is associated with poor survival…”
BackgroundNeuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E. K., Blaszkowsky, L. S., Brock, P. L., Chan, J., Das, S., Dickson, P. V., Fanta, P. T., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 642
Realizing the promise of cancer predisposition genes
Rahman, N. (2014) · Nature · doi:10.1038/nature12981 · Cited by 631
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Dahia, P. L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3648 · Cited by 545
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine
Favier, J., Amar, L., & Gimenez‐Roqueplo, A. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.188 · Cited by 484
Personalized Management of Pheochromocytoma and Paraganglioma
Nölting, S., Bechmann, N., Taïeb, D., Beuschlein, F., Faßnacht, M., Kroiß, M., Eisenhofer, G., Grossman, A. B., & Pacák, K. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab019 · Cited by 441
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacák, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 330
Mitochondrial complex ii: At the crossroads
Bezawork-Geleta, A., Rohlena, J., Dong, L., Pacak, K., & Neuzil, J. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.01.003 · Cited by 295
Rednam, S. P., Erez, A., Druker, H. A., Janeway, K. A., Kamihara, J., Kohlmann, W. K., Nathanson, K. L., States, L. J., Tomlinson, G. E., Villani, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0547 · Cited by 282
The NGS in PPGL (NGSnPPGL) Study Group, Toledo, R. A., Burnichon, N., Cascón, A., Benn, D. E., Bayley, J., Welander, J., Tops, C. M. J., Firth, H. V., Dwight, T., et al. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.185 · Cited by 276
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
2-Oxoglutarate-dependent dioxygenases in cancer
Losman, J.-A., Koivunen, P., & Kaelin, W. G. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-00303-3 · Cited by 241
Worms under stress: C. elegans stress response and its relevance to complex human disease and aging
Rodríguez, M. G., Snoek, B. L., de Bono, M., & Kammenga, J. E. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.01.010 · Cited by 225
Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
Mafficini, A., & Scarpa, A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00160 · Cited by 221
Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment
Martucci, V. L., & Pacák, K. (2014) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2014.01.001 · Cited by 212
An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma
Buffet, A., Burnichon, N., Favier, J., & Gimenez‐Roqueplo, A. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101416 · Cited by 194
García‐Carbonero, R., Teresa, F. M., Mercader-Cidoncha, E., Mitjavila, M., Robledo, M., Tena, I., Álvarez-Escolá, C., Arístegui, M., Bella-Cueto, M. R., Albiach, C. F., et al. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02622-9 · Cited by 188
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
Sanghani, N. S., & Haase, V. H. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.04.004 · Cited by 188
Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas
Pamporaki, C., Hamplová, B., Peitzsch, M., Prejbisz, A., Beuschlein, F., Timmers, H. J. L. M., Faßnacht, M., Klink, B., Lodish, M. B., Stratakis, C. A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3829 · Cited by 183
Self-citationDIAGNOSIS OF ENDOCRINE DISEASE: Biochemical diagnosis of phaeochromocytoma and paraganglioma
van Berkel, A., Lenders, J. W. M., & Timmers, H. J. L. M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0882 · Cited by 177
Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction
Jochmanová, I., Yang, C., Zhuang, Z., & Pacák, K. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt201 · Cited by 176
Self-citationWelander, J., Stenman, A., Juhlin, C. C., Wiseman, R. W., Bäckdahl, M., Höög, A., Larsson, C., Gimm, O., & Söderkvist, P. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-4375 · Cited by 177
A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma
Lorenzo, F. R., Yang, C., Ng Tang Fui, M., Vankayalapati, H., Zhuang, Z., Huynh, T., Grossmann, M., Pacak, K., & Prchal, J. T. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0967-z · Cited by 171
Self-citationComino-Méndez, I., de Cubas, A. A., Bernal, C., Álvarez-Escolá, C., Sánchez-Malo, C., Ramírez-Tortosa, C. L., Pedrinaci, S., Rapizzi, E., Ercolino, T., Bernini, G., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt069 · Cited by 169
Pheochromocytoma and Paraganglioma
Fishbein, L. M. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.09.006 · Cited by 161
Hypoxia-inducible factors and diabetes
Gunton, J. E. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137556 · Cited by 159
New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia
Pacák, K., Jochmanová, I., Prodanov, T., Yang, C., Merino, M. J., Fojo, T., Prchal, J. T., Tischler, A. S., Lechan, R. M., & Zhuang, Z. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1912 · Cited by 157
Self-citationYang, C., Zhuang, Z., Fliedner, S. M. J., Shankavaram, U. T., Sun, M. G., Bullova, P., Zhu, R., ELKAHLOUN, A. G., Kourlas, P. J., Merino, M. J., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1205-7 · Cited by 153
Self-citationCrona, J., Verdugo, A. D., Maharjan, R., Stalberg, P. L. H., Granberg, D. O., Hellman, P., & Björklund, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4257 · Cited by 154
Turková, H., Prodanov, T., Malý, M., Martucci, V. L., Adams, K. T., Widimsky, J., Jr., Chen, C. C., Ling, A. L., Kebebew, E., Stratakis, C. A., et al. (2015) · Endocrine Practice · doi:10.4158/ep15725.or · Cited by 143
Self-citationIn vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas
Toledo, R. A., Qin, Y., Srikantan, S., Morales, N. P., Li, Q., Deng, Y., Kim, S.-W., Pereira, M. A. A., Toledo, S. P. A., Su, X., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0101 · Cited by 136
Comparative genomic investigation of high-elevation adaptation in ectothermic snakes
Li, J., Gao, Y., Xie, L., Deng, C., Shi, P., Guan, M.-L., Huang, S., Ren, J., Wu, D., Ding, L., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805348115 · Cited by 132
McMullin, M. F., Mead, A. J., Ali, S., Cargo, C. A., Chen, F. E., Ewing, J. C., Garg, M. K., Godfrey, A. L., Knapper, S., McLornan, D. P., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15647 · Cited by 131
Currás-Freixes, M., Inglada‐Pérez, L., Mančíková, V., Montero‐Conde, C., Letón, R., Comino‐Méndez, I., Apellániz-Ruiz, M., Sánchez, L. M. M., Sánchez-Covisa, M. A., Alcázar, V., et al. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103218 · Cited by 129
Zhang, Q., Lou, Y., Zhang, J., Fu, Q., Wei, T., Sun, X., Chen, Q., Yang, J., Bai, X., & Liang, T. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0689-5 · Cited by 127
Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases
Bento, C., Percy, M. J., Gardie, B., Maia, T. M., van Wijk, R., Perrotta, S., Ragione, F. D., Almeida, H., Rossi, C., Girodon, F., et al. (2013) · Human Mutation · doi:10.1002/humu.22448 · Cited by 130
Self-citationPheochromocytoma and paraganglioma syndromes: genetics and management update
Lefebvre, M., & Foulkes, W. D. (2013) · Current Oncology · doi:10.3747/co.21.1579 · Cited by 125
Taïeb, D., Jha, A., Treglia, G., & Pacák, K. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0165 · Cited by 120
Oxygen-sensing mechanisms across eukaryotic kingdoms and their roles in complex multicellularity
Hammarlund, E. U., Flashman, E., Mohlin, S., & Licausi, F. (2020) · Science · doi:10.1126/science.aba3512 · Cited by 120
Pillai, S., Gopalan, V., Smith, R. A., & Lam, A. K.-Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.022 · Cited by 113
Erythrocytosis: the HIF pathway in control
Franke, K., Gassmann, M., & Wielockx, B. (2013) · Blood · doi:10.1182/blood-2013-01-478065 · Cited by 116
Genomic Landscape of Pheochromocytoma and Paraganglioma
Jochmanová, I., & Pacák, K. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.11.001 · Cited by 111
Pheochromocytoma and Paraganglioma in Cyanotic Congenital Heart Disease
Opotowsky, A. R., Moko, L. E., Ginns, J. N., Rosenbaum, M., Greutmann, M., Aboulhosn, J., Hageman, A., Kim, Y. Y., Deng, L. X., Grewal, J., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3863 · Cited by 104
Pheochromocytoma and paraganglioma: from epidemiology to clinical findings
Aygün, N. (2020) · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital · doi:10.14744/semb.2020.18794 · Cited by 101
Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging
Alrezk, R., Suárez, A., Tena, I., & Pacák, K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00515 · Cited by 102
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia
Toledo, R. A., Jiménez, C., Armaiz-Peña, G., Arenillas, C., Capdevila, J., & Dahia, P. L. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac025 · Cited by 101
Mosaicism inHIF2A-Related Polycythemia-Paraganglioma Syndrome
Buffet, A., Smati, S., Mansuy, L., Menara, M., Bras, M. L., Heymann, M., Simian, C., Favier, J., Murat, A., Cariou, B., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2600 · Cited by 105
Yang, C., Sun, M. G., Matro, J. C., Huynh, T., Rahimpour, S., Prchal, J. T., Lechan, R. M., Lonser, R. R., Pacák, K., & Zhuang, Z. (2013) · Blood · doi:10.1182/blood-2012-10-460972 · Cited by 95
Self-citationThe HIF and other quandaries in VHL disease
Tarade, D., & Ohh, M. (2017) · Oncogene · doi:10.1038/onc.2017.338 · Cited by 93
Luchetti, A., Walsh, D. M., Rodger, F., Clark, G. R., Martin, T., Irving, R. M., Sanna, M., Yao, M., Robledo, M., Neumann, H. P. H., et al. (2015) · International Journal of Endocrinology · doi:10.1155/2015/138573 · Cited by 91
Camps, C., Petousi, N., Bento, C., Cario, H., Copley, R. R., McMullin, M. F., van Wijk, R., Ratcliffe, P. J., Robbins, P. A., & Taylor, J. C. (2016) · Haematologica · doi:10.3324/haematol.2016.144063 · Cited by 93
Belzutifan, a Potent HIF2α Inhibitor, in the Pacak–Zhuang Syndrome
Kamihara, J., Hamilton, K. V., Pollard, J. A., Clinton, C. M., Madden, J. A., Lin, J., Imamovic, A., Wall, C. B., Wassner, A. J., Weil, B. R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110051 · Cited by 89
Remacha, L., Comino‐Méndez, I., Richter, S., Contreras, L., Currás-Freixes, M., Pita, G., Letón, R., Galarreta, A., Torres‐Pérez, R., Honrado, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2250 · Cited by 98
Genetics of hereditary head and neck paragangliomas
Boedeker, C. C., Hensen, E. F., Neumann, H. P. H., Maier, W., van Nederveen, F. H., Suarez, C. M., Kunst, H. P. M., Rodrigo, J. P., Takes, R. P., Pellitteri, P. K., et al. (2013) · Head & Neck · doi:10.1002/hed.23436 · Cited by 88
Novel insights into the polycythemia–paraganglioma–somatostatinoma syndrome
Därr, R., Nambuba, J., Rivero, J. D., Janssen, I., Merino, M. J., Todorović, M., Balint, B., Jochmanová, I., Prchal, J. T., Lechan, R. M., et al. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0231 · Cited by 85
Self-citationPhaeochromocytoma and paraganglioma
Fonseca, V. A., & Bouloux, P.-M. G. (1993) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80186-7 · Cited by 84
Eisenhofer, G., Klink, B., Richter, S., Lenders, J. W. M., & Robledo, M. (2017) · Europe PMC (PubMed Central) · Cited by 84
Davis, L., Recktenwald, M., Hutt, E., Fuller, S., Briggs, M., Goel, A., & Daringer, N. (2022) · Cancers · doi:10.3390/cancers14051259 · Cited by 83
Hypoxia and hypoxia-inducible factors in neuroblastoma
Påhlman, S., & Mohlin, S. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2701-1 · Cited by 83
Update on mutations in the HIF: EPO pathway and their role in erythrocytosis
Lappin, T. R. J., & Lee, F. S. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100590 · Cited by 86
Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
Ilanchezhian, M., Jha, A., Pacák, K., & Rivero, J. D. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00787-z · Cited by 82
Qin, N., de Cubas, A. A., García-Martín, R., Richter, S., Peitzsch, M., Menschikowski, M., Lenders, J. W. M., Timmers, H. J. L. M., Mannelli, M., Opocher, G., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28868 · Cited by 81
Paragangliomas/Pheochromocytomas: Clinically Oriented Genetic Testing
Martins, R., & Bugalho, M. J. (2014) · International Journal of Endocrinology · doi:10.1155/2014/794187 · Cited by 82
The genomic landscape of phaeochromocytoma
Flynn, A., Benn, D. E., Clifton-Bligh, R. J., Robinson, B. G., Trainer, A. H., James, P. A., Hogg, A., Waldeck, K., George, J., Li, J., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4503 · Cited by 81
Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma
Welander, J., Stenman, A., Brauckhoff, M., Bäckdahl, M., Larsson, C., Gimm, O., & Söderkvist, P. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0384 · Cited by 82
Currás-Freixes, M., Piñeiro-Yáñez, E., Montero‐Conde, C., Apellániz-Ruiz, M., Calsina, B., Mančíková, V., Remacha, L., Richter, S., Ercolino, T., Rogowski-Lehmann, N., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.04.009 · Cited by 78
Gupta, G., & Pacák, K. (2017) · Endocrine Practice · doi:10.4158/ep161718.ra · Cited by 77
Clinical Presentation and Diagnosis of Neuroendocrine Tumors
Vinik, A. I., & Chaya, C. (2015) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.08.006 · Cited by 76
Semenza, G. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102602 · Cited by 74
Pheochromocytoma and Paraganglioma
Pacák, K., & Wimalawansa, S. J. (2015) · Endocrine Practice · doi:10.4158/ep14481.ra · Cited by 71
Adrenal Medullary Hyperplasia Is a Precursor Lesion for Pheochromocytoma in MEN2 Syndrome
Korpershoek, E., Petri, B., Post, E., van Eijck, C. H. J., Oldenburg, R. A., Belt, E. J. T., de Herder, W. W., de Krijger, R. R., & Dinjens, W. N. M. (2014) · Neoplasia · doi:10.1016/j.neo.2014.09.002 · Cited by 68
Juhlin, C. C., Stenman, A., Haglund, F., Clark, V. E., Brown, T. C., Baranoski, J. F., Bilgüvar, K., Goh, G., Welander, J., Svahn, F., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22267 · Cited by 69
EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease
Vaidya, A., Flores, S. K., Cheng, Z.-M., Nicolas, M. M., Deng, Y., Opotowsky, A. R., Lourenço, D. M., Barletta, J. A., Rana, H. Q., Pereira, M. A. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1716652 · Cited by 67
GEP- NETS UPDATE: Genetics of neuroendocrine tumors
Crona, J., & Skogseid, B. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0972 · Cited by 71
Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease
Liang, R. H.-S., & Ghaffari, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14194 · Cited by 69
Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma
Kľučková, K., & Tennant, D. A. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2801-6 · Cited by 68
Genetic bases of pheochromocytoma and paraganglioma
Cascón, A., Calsina, B., Monteagudo, M., Mellid, S., Díaz‐Talavera, A., Currás-Freixes, M., & Robledo, M. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0167 · Cited by 65
Antonio, K. L., Valdez, M. M. N., MERCADO-ASIS, L. B., Taïeb, D., & Pacák, K. (2020) · Gland Surgery · doi:10.21037/gs.2019.10.25 · Cited by 65
HIF2AMutations in Paraganglioma with Polycythemia
Favier, J., Buffet, A., & Gimenez‐Roqueplo, A. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1211953 · Cited by 65
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views
Gangat, N., Szuber, N., Pardanani, A. D., & Tefferi, A. (2021) · Leukemia · doi:10.1038/s41375-021-01290-6 · Cited by 65
Rethinking pheochromocytomas and paragangliomas from a genomic perspective
Castro‐Vega, L. J., Lussey‐Lepoutre, C., Gimenez‐Roqueplo, A., & Favier, J. (2015) · Oncogene · doi:10.1038/onc.2015.172 · Cited by 64
Phaeochromocytoma and Paraganglioma
Gunawardane, P. T. K., & Grossman, A. B. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_76 · Cited by 62
MANAGEMENT OF ENDOCRINE DISEASE: Clinical management of paragangliomas
Corssmit, E. P. M., & Romijn, J. A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0396 · Cited by 61
Baysal, B. E., & Maher, E. R. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0226 · Cited by 62
Progenitor Cell Line (hPheo1) Derived from a Human Pheochromocytoma Tumor
Ghayee, H. K., Bhagwandin, V. J., Stastny, V., Click, A., Ding, L.-H., Mizrachi, D., Zou, Y. S., Chari, R., Lam, W. L., Bachoo, R. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065624 · Cited by 60
Korpershoek, E., Koffy, D., Eussen, B. H. J., Oudijk, L., Papathomas, T. G., van Nederveen, F. H., Belt, E. J. T., Franssen, G. J. H., Restuccia, D. F., Krol, N. M. G., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2592 · Cited by 60
HIF-2α is essential for carotid body development and function
Macias, D., Cowburn, A. S., Torres-Torrelo, H., Ortega-Sáenz, P., López-Barneo, J., & Johnson, R. S. (2018) · eLife · doi:10.7554/elife.34681 · Cited by 59
Casey, R. T., Hendriks, E., Deal, C., Waguespack, S. G., Wiegering, V., Redlich, A., Akker, S. A., Prasad, R., Faßnacht, M., Clifton-Bligh, R. J., et al. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01024-5 · Cited by 63
Rao, J. U., Engelke, U. F. H., Rodenburg, R. J., Wevers, R. A., Pacák, K., Eisenhofer, G., Qin, N., Küsters, B., Goudswaard, A. G., Lenders, J. W. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3922 · Cited by 58
Pheochromocytoma: A Genetic And Diagnostic Update
MERCADO-ASIS, L. B., Wolf, K. I., Jochmanová, I., & Taïeb, D. (2017) · Endocrine Practice · doi:10.4158/ep-2017-0057 · Cited by 58
de Cubas, A. A., Leandro-Garcia, L. J., Schiavi, F., Mančíková, V., Comino‐Méndez, I., Inglada‐Pérez, L., Pérez‐Martínez, M., Ibarz, N., Ximénez‐Embún, P., López-Jiménez, E. A., et al. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0183 · Cited by 62
Precision medicine in pheochromocytoma and paraganglioma: current and future concepts
Björklund, P., Pacák, K., & Crona, J. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12507 · Cited by 59
Taïeb, D., Yang, C., Delenne, B., Zhuang, Z., Barlier, A., Sebag, F. A., & Pacák, K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1217 · Cited by 59
Self-citationTargeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy
Zhang, X., & Sjöblom, T. (2021) · Pharmaceuticals · doi:10.3390/ph14010057 · Cited by 56
Okubo, Y., Yoshioka, E., Suzuki, M., Washimi, K., Kawachi, K., Kameda, Y., & Yokose, T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00291 · Cited by 56
Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options
Nölting, S., Grossman, A. B., & Pacák, K. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0715-1888 · Cited by 58
Metadata
- Authors
- Zhuang, Z., Yang, C., Lorenzo, F., Merino, M., Fojo, T., Kebebew, E., Popovic, V., Stratakis, C. A., Prchal, J. T., & Pacak, K.
- Affiliations
- National Institutes of Health (US)
- National Institute of Neurological Disorders and Stroke (US)
- Veterans Health Administration (US)
- National Cancer Institute (MY)
- National Cancer Institute (UA)
- University of Belgrade (RS)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (US)
- University of Utah (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-09-06
- Volume
- 367
- Issue
- 10
- Pages
- 922-930
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3432945
- OpenAlex
- W2142033642
- Cited by
- 397
- References
- 26
- Citations by year
- 2026: 22 · 2025: 12 · 2024: 22 · 2023: 18 · 2022: 20 · 2021: 29 · 2020: 24 · 2019: 24 · 2018: 32 · 2017: 43 · 2016: 27 · 2015: 31 · 2014: 47 · 2013: 42 · 2012: 2
- FWCI
- 39.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (P01CA108671)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (ZIAHD008735)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- HIF-2α, paraganglioma, polycythemia, somatostatinoma, gain-of-function mutations, protein half-life, prolyl hydroxylation, VHL, succinate dehydrogenase, pheochromocytoma
- MeSH terms
- Abdominal Neoplasms, Endothelial PAS Domain-Containing Protein 1, Adolescent, Adrenal Gland Neoplasms, Adult, DNA Mutational Analysis, Female, Humans, Hydroxylation, Mutation, Pancreatic Neoplasms, Paraganglioma, Polycythemia, Somatostatinoma, Transcription, Genetic, Up-Regulation, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
